Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
July 28th, 2022
1.9K views
This protocol describes a method to establish and perform a scratch wound assay on two-dimensional (2D) monolayers derived from three-dimensional (3D) enteroids isolated from non-human primate ileum.
Overview
This protocol describes a method to establish and perform a scratch wound assay on two-dimensional (2D) monolayers derived from three-dimensional (3D) enteroids isolated from non-human primate ileum. This technique allows for real-time visualization of wound closure in a preterm 2D enteroid monolayer model of intestinal regeneration.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Regenerative Medicine
Background
- The scratch wound assay is commonly used for studying cell migration and wound healing.
- Enteroid-derived monolayers represent all major cell types of the small intestine.
- This model is particularly relevant for studying preterm mammalian gut regeneration.
- Traditional models often rely on transformed colorectal cancer cell lines, which do not accurately represent normal intestinal physiology.
Purpose of Study
- To develop a reliable method for studying intestinal regeneration using enteroid-derived monolayers.
- To enable real-time monitoring of wound healing processes.
- To provide a more physiologically relevant model for preterm gut studies.
Methods Used
- Thawing and diluting ECM-based hydrogel for coating tissue culture plates.
- Disrupting 3D enteroids to create a monolayer and culturing it until confluency.
- Creating a linear scratch in the monolayer to initiate the wound healing process.
- Using live cell analysis software to monitor and analyze wound closure over time.
Main Results
- The protocol successfully establishes a scratch wound assay on enteroid-derived monolayers.
- Real-time imaging allows for detailed observation of wound healing dynamics.
- The method demonstrates the potential for studying regenerative processes in a preterm gut model.
- Results indicate that the enteroid-derived model is a viable alternative to traditional cell lines.
Conclusions
- This protocol provides a novel approach for studying intestinal regeneration.
- It highlights the importance of using physiologically relevant models in regenerative medicine research.
- The findings may contribute to better understanding of gut healing processes in preterm infants.
Frequently Asked Questions
What is a scratch wound assay?
A scratch wound assay is a laboratory technique used to study cell migration and wound healing by creating a physical scratch in a cell monolayer.
Why use enteroid-derived monolayers?
Enteroid-derived monolayers better represent the cellular composition and physiology of the small intestine compared to traditional cancer cell lines.
How is real-time visualization achieved?
Real-time visualization is achieved using live cell imaging techniques that allow monitoring of cell behavior over time.
What are the advantages of this method?
This method provides a more accurate model for studying intestinal regeneration and allows for detailed observation of cellular responses.
Can this protocol be applied to other types of cells?
While this protocol is designed for intestinal cells, similar methods can be adapted for other cell types in regenerative studies.
What is the significance of using a preterm gut model?
A preterm gut model is significant for understanding the unique challenges and healing processes that occur in premature infants.
Executive Industry Relevance
Enteroid-derived monolayer scratch wound assays provide a physiologically relevant platform for interrogating epithelial healing mechanisms in preterm small intestine. This model enables quantitative, real-time assessment of regenerative responses to candidate agents such as hyaluronan 35 kDa, supporting predictive confidence in early-stage target validation. The approach addresses a critical gap in translational continuity between discovery biology and preclinical intestinal regeneration studies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic interrogation of epithelial repair pathways in a disease-relevant, non-transformed system.
- Supports functional target validation by quantifying wound closure and cell migration in response to candidate molecules.
- Facilitates biological de-risking by modeling preterm intestinal regeneration more accurately than cancer cell lines.
Screening & Assay Development
- Provides a standardized, reproducible assay for evaluating pro-regenerative compounds in intestinal epithelium.
- Generates quantitative wound closure metrics suitable for comparative screening of multiple conditions or agents.
- Enables live-cell imaging and automated analysis for scalable, high-content data acquisition.
Translational & Preclinical Research
- Aligns with disease-relevant biology for preterm intestinal injury and regeneration studies.
- Supports continuity from in vitro discovery to preclinical validation by modeling primary tissue responses.
- Reduces translational risk by providing predictive data on epithelial healing mechanisms.
Pipeline & Workflow Integration
This enteroid-derived monolayer assay bridges early discovery and preclinical research by enabling hypothesis-driven testing of regenerative agents in a physiologically relevant context.
- Discovery Biology: Supports null hypothesis testing of candidate pro-regenerative factors on epithelial wound closure.
- Screening: Delivers reproducible, quantitative wound healing outputs for compound prioritization.
- Analytics: Provides time-resolved, image-based measurements of cell migration and proliferation using standardized plugins.
- Translational Research: Models preterm intestinal regeneration, informing biomarker and therapeutic strategy development.
- Enterprise Reuse: Establishes a reusable platform for cross-program evaluation of epithelial repair mechanisms.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation and mechanistic de-risking for intestinal regeneration.
- Operational Value: Standardizes wound healing assays with automated imaging and analysis workflows.
- Strategic Value: Improves go/no-go decision-making by providing robust, quantitative data on candidate efficacy.
- Portfolio Impact: Enables risk-adjusted prioritization of regenerative agents for preclinical advancement.
Implementation Considerations
- Requires expertise in enteroid culture and monolayer generation from primary intestinal tissue.
- Needs access to live-cell imaging platforms and compatible analysis software (e.g., ImageJ with wound healing plugins).
- Demands rigorous cross-team standardization of assay setup, imaging intervals, and data analysis parameters.
- Adaptation to other tissue types or species may require protocol optimization and validation.
- Short-lived nature of monolayers necessitates precise timing and rapid execution of experimental workflows.
Biopharma FAQs
Why does null hypothesis testing in scratch wound assays matter for target validation?
Null hypothesis testing in the enteroid-derived scratch wound assay enables objective evaluation of whether candidate agents like HA35 significantly accelerate epithelial healing compared to controls. This approach provides quantitative evidence for or against target engagement, supporting robust early-stage validation decisions.
How does independent variable isolation in HA35 treatment fit the discovery pipeline?
By isolating HA35 concentration as the independent variable and controlling other assay conditions, the protocol allows clear attribution of observed wound healing effects to the test agent. This isolation is essential for mechanistic de-risking and informs downstream screening and optimization workflows.
What do quantitative wound closure measurements enable in R&D workflows?
Quantitative wound closure metrics, derived from time-lapse imaging and automated analysis, enable direct comparison of treatment efficacy and dose response. These outputs support data-driven compound prioritization and facilitate reproducibility across discovery and preclinical teams.
Why are replication requirements critical for cross-functional collaboration in this assay?
Replication ensures that wound healing effects observed with HA35 or controls are consistent and statistically robust, enabling reliable data sharing and interpretation across biology, screening, and translational research teams. This underpins confidence in advancing candidates through the pipeline.
What statistical analysis capabilities are required before implementing wound healing quantification?
Implementation requires statistical tools to analyze wound closure rates, assess significance between treatment groups, and control for variability. These capabilities are essential for rigorous interpretation of assay outputs and for supporting go/no-go decisions in early discovery.
Chapters in this video
0:04
Introduction
0:46
Enteroid Monolayer Formation
3:47
Monolayer Treatment and Scratch Wound Assay
6:36
Scratch Wound Analysis
7:38
Results: Enteroid Generation and Enteroid-Derived Monolayer Wound Healing Assay Procedure, Images, Analysis, and the Effect of HA35 on Wound Healing
8:58
Conclusion
